Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Caponigro, F.
Right arrow Articles by Comella, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caponigro, F.
Right arrow Articles by Comella, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:199-202, 2001
© 2001 European Society for Medical Oncology

research-article

Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: A phase II study of the Southern Italy Cooperative Oncology Group (SICOG)

F. Caponigro1,, E. Massa2, G. Rosati3, M. Biglietto4, L. De Lucia5, C. Sguotti6, P. Sganga6, A. Avallone1, P. Comella1, G. Mantovani1 and G. Comella1

1Medical Oncology A, National Tumor Institute Naples
2Institute of Oncology. University of Cagliari Cagliari
3Medical Oncology. S Carlo Hospital Potenza
4Medical Oncology, Cardarelli Hospital Naples
5Azienda Ospedaliera Caserta, Caserta
6Rhone-Poulene, Rorer, Origgio, Italy

Istituto Nazionale Tumori ‘Fondazione G. Pascal’Via M. Semmola 80131 Napoli Italyfracap{at}sirio-oncology.it

BACKGROUND:: Docetaxel is one of the most promising new drugs against squamous-cell carcinoma of the head and neck (SCCHN), while cisplatin is one of the most active single agents. A phase 1 study has shown the feasibility of the combination of the two drugs, and activity in SCCHN has been seen.

PATIENTS AND METHODS:: Patients with locally advanced, inoperable, or metastatic SCCHN, never pretreated with radiotherapy or chemotherapy, received three courses of docetaxel 75 mg/m2 and cisplatin 100 mg/m2 every three weeks. Thereafter. responsive metastatic patients received additional chemotherapy, while patients with locally advanced disease underwent radiation therapy.

RESULTS:: Forty-six patients (forty-five with locally advanced, one with metastatic disease) were entered into the study. Ten patients did not complete three courses of chemotherapy be cause of early death; one patient discontinued treatment after one course. Twenty-one objective responses were observed (46%, 95% confidence interval (CI): 31%–60%). including five complete responses (11%) and sixteen partial responses (35%). Following induction chemotherapy plus radiation therapy. 9 of 21 evaluable patients were rendered disease free, while 8 additional patients had a partial response. After a median follow-up of 18 months, the median duration of response was 12 months, (range 3–25+), and the median overall survival was 11 months. Six early deaths were considered possibly treatment-related (sepsis following grade 4 neutropenia in two cases, hypovolernic shock following severe diarrhea in four cases). Neutropenia was the most severe toxicity (grade 3–4 in 28 patients, median duration 4 days); diarrhea and vomiting were the most troublesome non-haematologic toxicities (grade 4 in 4 and 3 patients, respectively).

CONCLUSIONS:: The combination of docetaxel and cisplatin is active in SCCHN, but toxicity is substantial. This schedule does not appear to offer any advantage compared with conventional regimens.

cisplatin, docetaxel, squamous-cell carcinoma of the head and neck


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
E. P. Hui, B. B. Ma, S. F. Leung, A. D. King, F. Mo, M. K. Kam, B. K. Yu, S. K. Chiu, W. H. Kwan, R. Ho, et al.
Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma
J. Clin. Oncol., January 10, 2009; 27(2): 242 - 249.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Zhang, C. Zhao, P.-J. Peng, L.-X. Lu, P.-Y. Huang, F. Han, and S.-X. Wu
Phase III Study Comparing Standard Radiotherapy With or Without Weekly Oxaliplatin in Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Preliminary Results
J. Clin. Oncol., November 20, 2005; 23(33): 8461 - 8468.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Schrijvers, C. Van Herpen, J. Kerger, E. Joosens, C. Van Laer, A. Awada, D. Van den Weyngaert, H. Nguyen, C. Le Bouder, J. A. Castelijns, et al.
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study
Ann. Onc., April 1, 2004; 15(4): 638 - 645.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
R J Sanderson, J A D Ironside, and W. I Wei
Squamous cell carcinomas of the head and neck * Commentary: Head and neck carcinomas in the developing world
BMJ, October 12, 2002; 325(7368): 822 - 827.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.